Patent · US Active

Anti-CEACAM5 antibodies and uses thereof

US10457739B2 · kind B2 · utility

3Cited by

43References

40Claims

0Family size

Assignee

Sanofi · FR

Inventors

Pierre-Francois Berne · Paris, FR
Francis Blanche · Paris, FR
Herve Bouchard · Thiais, FR
Beatrice Cameron · Paris, FR
Tarik Dabdoubi · Paris, FR
Stéphanie DECARY · Paris, FR
Paul FERRARI · Paris, FR
Alexey Rak · Paris, FR

Key dates

Filing date	Mar 1, 2017
Grant date	Oct 29, 2019
Priority date	—
Expiry date	Mar 1, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70503
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.